Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms OrPHeUS
- Sponsors Actelion Pharmaceuticals
- 13 Nov 2017 Planned End Date changed from 31 Dec 2018 to 15 Jan 2018.
- 13 Nov 2017 Planned primary completion date changed from 31 Dec 2018 to 15 Jan 2018.
- 22 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.